Not the magnesium
A little more detail on the aspirin/cancer study. You will note that
even the 75 mg aspirin worked too. None of the 75 or other low dose
aspirin that I've seen are buffered. I seriously doubt that whether or not
the 300 mg variety was required to be buffered was even a consideration.
Also notice in the 2nd article that just 1/4 aspirin with milk before bedtime
for people over 45 cut "mortality" by 10%.
Then in the 3rd link you will find that aspirin is a wonder drug and that it
prevents several cancers.
It's too easy, too simple, and nobody's making a buck on it (like garlic) so
no wonder the naysayers are coming out of the woodwork.
http://www.telegraph.co.uk/health/healthnews/8853310/Aspirin-cuts-bowel-cance...
Aspirin cuts bowel cancer risk by up to two-thirds
Taking just two pills of aspirin a day can cut the risk of bowel cancer by
almost two-thirds for those at the highest risk, research has found.
Thousands of lives could be saved if people with a particular hereditary
condition took aspirin daily, suggests the British-led study.
Scientists have described the results, published in The Lancet, as
"the icing on the cake" after more than two decades of research into
aspirin's effect on cancer.
Today's study specifically looks at the preventative effect in those with a
hereditary condition called Lynch Syndrome, thought to affect about 60,000
people in Britain. Despite being present in only one in 1,000 people, it is
responsible for one in 30 bowel cancers.
But the researchers said the study added powerful new evidence that aspirin
protected against bowel cancer in the wider population too.
Bowel cancer is the third most common cancer in Britain, with 40,000 new
cases annually and over 16,000 deaths.
The study of 861 middle-aged people with Lynch Syndrome found those who took
two 300mg pills daily for two years, were 63 per cent less likely to have
developed bowel cancer five years later, than those given a placebo.
The results are critical for those with the syndrome because their lifetime
risk of developing bowel cancer is as high as one in two.
Professor Sir John Burn from Newcastle University, who led the international
project, said he and colleagues were "very pleased" with the
"impressive" results.
He and Professor Tim Bishop, of Leeds University, suggested those with Lynch
Syndrome should start taking aspirin from the age of 20, as they can develop
cancers well before middle age.
They estimated that, excluding the young and the very old, about 30,000 of
them should be taking aspirin.
Prof Burn said: "If we were to put them on aspirin now, we would stop
about 10,000 cancers over 30 years."
However, only about 10 per cent of those with Lynch Syndrome know they have
it.
The results follow a landmark study led by Professor Peter Rothwell of Oxford
University, published a year ago.
It found people taking low dose (75mg) aspirin daily for five years were 25
per cent less likely to have developed bowel cancer after 20 years than those
not taking it.
The participants had been taking the drug to prevent heart disease and
stroke. They were drawn from the general population, not just those with Lynch
Syndrome.
Prof Rothwell consequently suggested everybody should consider taking low
dose aspirin daily from the age of 45, although he said it was a matter for
individuals to decide "rather than us making definitive statements".
Professors Burn and Bishop echoed that advice. They have already advised
their patients and volunteers with Lynch Syndrome to take aspirin, and said
others needed to consider the "sliding scale" of aspirin's benefits
and risks depending on their circumstances.
The drug is known to increase slightly the chance of stomach and intestinal
ulcers, particularly in the elderly.
While Prof Rothwell's work convinced many that aspirin helped prevent cancer,
because it was an observational study it could not prove cause and effect.
Today's study was different, said Prof Burn, being "the first randomised
controlled trial [of aspirin] undertaken with cancer as an end point".
The group now aims to determine the best dose for those with Lynch Syndrome
and wants to recruit 3,000 people around the world to do so. They will be given
either 600, 300, or 75mg daily.
David Willetts, the Universities and Science Minister, welcomed the
"groundbreaking study" as "an excellent achievement for the UK
research base".
He said: "It has the potential to save thousands of lives worldwide and
is clear evidence of the value of long-term studies showing simple steps that
can be taken to improve people's lives."
*The NHS will have to deal with 45 per cent more cancer cases by 2030, a
leading charity is warning.
Cancer Research UK predicts the number will climb from about 298,000 in 2007
in 432,000 in 2030, which could "overwhelm NHS resources".
The biggest reason behind the rise is the ageing population, but changing
lifestyles are also a factor. Cancers of the mouth, kidney and liver are
forecast to be among the biggest risers, due in part to smoking and drinking.
http://www.telegraph.co.uk/health/healthnews/8184776/Aspirin-the-wonder-drug-...
Aspirin 'the wonder drug' fights off cancer as well as
heart disease
Taking a quarter of an aspirin with milk just before you go to bed every
night could reduce your chance of dying in middle age by a tenth, the biggest
study into the drug has found.
The "exciting" evidence shows that the benefits of those aged
over 45 regularly taking the cheap painkiller "drowns out" any side
effects that could occur from the regular medication.
It is so compelling that the researchers are convinced it will lead to a
change in public health prevention guidelines.
Doctors have known for a long time that aspirin, which thins the blood, can
protect against heart disease and stroke but the latest research shows the
"wonder drug" has an even stronger effect on cancer.
At the moment an increase in the risk of stomach and intestinal bleeding
associated with the pill has scared many health experts off from recommending
it to the healthy general public, but this new effect could tip the balance,
claim the study authors.
Anyone with a family history of heart disease or cancer, would be
especially helped by taking the painkiller as a preventive medicine.
A team of researchers led by Professor Peter Rothwell at Oxford University
reviewed the data from eight separate trials on aspirin which together included
25,570 patients taking the drug regularly for on average four years.
They found that "all cause mortality" was reduced by 10 per cent
for those taking a 75mg dose of the drug.
A normal over-the-counter pill contains 300mg.
For individual cancers the effect could be even stronger. The 20-year risk
for prostate cancer was reduced by about 10 per cent, for lung cancer 30 per
cent, bowel cancer 40 per cent and oesophageal or throat cancer by 60 per cent.
The study, published in the Lancet, suggests greater aspirin use could
potentially save thousands of lives a year in relation to cancer alone.
Combined, all cancers claim more than 150,000 lives in Britain every year,
while cardiovascular disease accounts for some 200,000 deaths.
Prof Rothwell, 46, who started taking aspirin two years ago, said it was
likely to have a major impact on public health – and be even more effective
than screening.
"The size of the effect of cancer is that it does more or less drown out
those sort of risks," he said.
"I think it is not for me the person who has done the research to make
recommendations but I suspect that the guidelines will be updated as a result of
these findings.
"This is likely to be much more effective than screening.
"It looks as though as there is a pretty large benefit in terms of
reducing cancer and the risks are really pretty low.
"It looks likely the longer you take aspirin, the greater the
benefit."
Prof Rothwell believes that the sensible time to start taking aspirin would
be in the early to mid 40s when the risk of cancers start to go up.
Prof Peter Elwood, of Cardiff University’s School of Medicine, conducted
the first trial into the effect of aspirin on heart disease in the 1970s,
started taking the drug about that time.
Now 80, he believes the risks are "trivial" compared with the
benefits.
"It is very exciting evidence and should be investigated more
fully," he said.
"It really is a remarkable drug."
It is just latest claim for aspirin which was formulated as a painkiller more
than a century ago. It is now linked with helping in diseases ranging from heart
disease to cancer to dementia.
Advocates believe that its active ingredient is akin to a vitamin that almost
everybody should take, as our modern diet does not provide it.
It is thought that it works in cancer because it boosts the body's ability to
root out, repair or kill rogue cells that can develop into cancer.
For heart disease it thins the blood and reduces the risk of clotting.
The researchers believe that the optimal time for taking the tablet would be
between 45 and 75 years old – before which the risk of cancer is to low –
and after which the risk of internal bleeding is too high.
If taken with milk at night it could be even more effective as calcium is
thought to boost aspirin's effect and the active ingredient of the pill is more
powerful during sleep.
They believe that it would be effective against breast and ovarian cancers
but there were too few patients studied to get a definitive result.
"Perhaps the most important finding for the longer-term is the proof of
principle that cancers can be prevented by simple compounds like aspirin and
that 'chemoprevention' is therefore a realistic goal for future research with
other compounds," said Prof Rothwell.
Prof Alastair Watson, Professor of Translational Medicine at the University
of East Anglia, said the study was a very important development.
"It is further proof that aspirin is, by a long way, the most amazing
drug in the world," he said.
Cancer Research UK described the study as "promising".
But the charity warned that patients should consult their GP before deciding
to take aspirin daily because of the drug's side effects.
A spokesman for the National Institute for Health and Clinical Excellence
(NICE) said it would take into account the new evidence when reviewing it
guidelines.
"We do review and update all our guidance on a regular basis, and if
there is new evidence that we think might change any of our existing
recommendations, then we will take that into account, " he said.
A Department of Health spokesman said: "We welcome this addition to the
evidence base and note that more research is required before clear conclusions
can be drawn on the implications for clinical practice."
http://www.telegraph.co.uk/health/healthnews/8184543/Aspirin-the-wonder-drug....
<snip>
Pregnant women with certain auto-immune conditions or high blood pressure are
also prescribed low doses of aspirin to reduce the risk of miscarriage, pre-eclampsia,
low birthweight and foetal death.
The latest research is now showing that aspirin can reduce the risk of
several cancers including bowel, prostate, throat and lung and possibly breast
and ovarian.
It is thought the way aspirin reduces the risk of some cancers is by blocking
an enzyme called Cox2 which is drives some forms of cancer.
New research is emerging that aspirin may be beneficial in preventing
dementia as well although it is inconclusive and more evidence is needed. This
may be because of the reduction in strokes and associated damage and its
anti-inflammatory effect which would protect the brain from build up of certain
proteins associated with dementia.
<snip>